Concept
Results of Studying the effect of ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in COVID-19 Patients with Hypertension (Wuhan, China)
- Patients taking ACEIs/ARBs had a higher prevalence of coronary artery disease
- Patients not taking ACEIs/ARBs had higher alkaline phosphate levels
- For the most part, all patients had similar comorbidities and laboratory profile results, such as blood cell counts, inflammatory markers, renal and liver function tests, and cardiac biomarkers
- ACEI/ARB treatment and calcium channel blockers did not affect the frequency of severity of illness, acute respiratory distress syndrome, and mortality among the hypertension patients
0
1
Updated 2020-07-23
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Discussion of Studying the effect of ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in COVID-19 Patients with Hypertension (Wuhan, China)
Results of Studying the effect of ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in COVID-19 Patients with Hypertension (Wuhan, China)
Stats for COVID-19 Patients with Hypertension (needs date of study)